A Study of Tucaresol in HIV-Infected Patients Who Are Taking Other Anti-HIV Drugs
Verified June 2001
Aaron Diamond AIDS Research Center
Information provided by (Responsible Party)
NIH AIDS Clinical Trials Information Service
First received: September 11, 2000
Last updated: June 23, 2005
Last Verified: June 2001
History of Changes
The purpose of this study is to see if it is safe to give tucaresol to HIV-infected patients who are taking combination anti-HIV therapy (HAART). This study also examines the effect tucaresol has on viral load (level of HIV in the body) when tucaresol is used with HAART.
Drug : Tucaresol
Primary Purpose: Treatment
|Official Title:||A Phase I Open-Label Dose Escalation Trial of Tucaresol in HIV-1 Infected Subjects Taking Potent Antiretroviral Therapy|
Further study details as provided by NIH AIDS Clinical Trials Information Service:
|Study Start Date:||June 2000|
Patients are enrolled sequentially into the next available dosage cohort. Each cohort receives a single dose of tucaresol, is observed for 2 weeks, and then receives 3 alternate-day doses of drug and careful safety monitoring, including 4 weeks follow-up after the final dose. Dose cohorts receive drug sequentially, the lowest-dose cohort receiving the drug first. Dose escalation may not proceed to the next higher-dose cohort until all patients from the prior lower-dose cohort have completed the 4-week follow-up after the multiple dosing, adverse events are within the described bounds, and the FDA has reviewed the safety information from the treated cohort and approved the dose escalation. The drug is administered 4 times within the 8 weeks of the study period. Weekly visits are required. Patients receive financial compensation.Eligibility
|Ages Eligible for Study:||18 Years and older|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Patients may be eligible for this study if they:
- Are at least 18 years old.
- Are HIV-positive.
- Have more than 300 CD4 T cells/microL at screening.
- Are taking certain anti-HIV drugs.
- Have been taking these anti-HIV drugs successfully for at least 6 months.
- Do not expect to change their anti-HIV therapy while they are in the study.
- Have had plasma viral load less than 50 copies/ml while on their anti-HIV therapy.
- Have viral load that cannot be detected at screening and baseline tests.
- Are able to complete weekly visits.
- Cannot give informed consent.
- Have abnormal laboratory test results at baseline.
- Are pregnant or breast-feeding.
- Have had certain short-term or long-term illnesses (such as heart disease, sickle cell disease, anemia, or lung problems).
- Have received a vaccination within the 30 days prior to enrollment.
- Have received any other experimental drug within 60 days of enrollment.
- Are taking abacavir (Ziagen, GW1592) or drugs that affect the immune system, such as IL-2, GM-CSF, corticosteroids, or cyclosporine.
- Have a history of tumors.
- Are actively using illegal drugs (methadone is allowed).
- Have hepatitis B or hepatitis C.
Patients will not be eligible for this study if they:
Contacts and LocationsChoosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00006209
Locations Show More
|United States, New York|
|New York, New York, United States, 10021|
Sponsors and CollaboratorsAaron Diamond AIDS Research Center
|Responsible Party:||Aaron Diamond AIDS Research Center|
|ClinicalTrials.gov Identifier:||NCT00006209 History of Changes|
|Other Study ID Numbers:||311A|
|Study First Received:||September 11, 2000|
|Last Updated:||June 23, 2005|
Keywords provided by NIH AIDS Clinical Trials Information Service:HIV-1
Drug Therapy, Combination
Additional relevant MeSH terms:
ClinicalTrials.gov processed this data on December 15, 2017
This information is provided by ClinicalTrials.gov.